Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period
Sign Up to like & getrecommendations! Published in 2021 at "Archives of Dermatological Research"
DOI: 10.1007/s00403-021-02200-7
Abstract: No data on real-life experiences of risankizumab efficacy and safety are reported, apart from two isolated case reports. We carried out a single-centre, prospective study to assess the efficacy and safety of risankizumab. Fourteen patients… read more here.
Keywords: week; efficacy safety; safety; results efficacy ... See more keywords
Risankizumab-Aggravated Crusted Scabies in a Patient with Down Syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Dermatology and Therapy"
DOI: 10.1007/s13555-020-00386-8
Abstract: Risankizumab, an interleukin (IL)-23 antagonist, is a highly effective treatment for moderate to severe psoriasis. Crusted scabies (CS) is a rare and severe form of scabies, occurring mainly in immunosuppressed patients and/or neurologically or mentally… read more here.
Keywords: aggravated crusted; patient syndrome; scabies patient; crusted scabies ... See more keywords
Deterioration of Health-Related Quality of Life After Withdrawal of Risankizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: A Machine Learning Predictive Model
Sign Up to like & getrecommendations! Published in 2021 at "Dermatology and Therapy"
DOI: 10.1007/s13555-021-00550-8
Abstract: Risankizumab has demonstrated efficacy in treating moderate-to-severe psoriasis. The phase-3 IMMhance trial (NCT02672852) examined the effect of continuing versus withdrawing from risankizumab treatment on psoriasis severity, including the Psoriasis Area and Severity Index (PASI) and… read more here.
Keywords: machine learning; model; psoriasis; withdrawal ... See more keywords
Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0794-1
Abstract: The history of psoriasis treatment has been marked by several milestones. Corticosteroids, cyclosporine, tumor necrosis factor alpha (TNF-α) inhibitors and, more recently, interleukin (IL)-17A inhibitors have revolutionized the treatment of psoriasis, each in its own… read more here.
Keywords: inhibition; treatment psoriasis; selective interleukin; psoriasis ... See more keywords
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Sign Up to like & getrecommendations! Published in 2019 at "The Lancet"
DOI: 10.1016/s0140-6736(19)30952-3
Abstract: BACKGROUND Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of risankizumab with… read more here.
Keywords: part; risankizumab; moderate severe; plaque psoriasis ... See more keywords
Potential Cerebrovascular Accident Signal for Risankizumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS).
Sign Up to like & getrecommendations! Published in 2022 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15581
Abstract: AIMS The interleukin-23 (IL-23) inhibitor risankizumab was recently approved for the treatment of moderate-to-severe plaque psoriasis in the U.S. Low rates of cerebrovascular accident (CVA) were observed in risankizumab-treated patients during clinical trials. The aim… read more here.
Keywords: cva; disproportionality; risankizumab; reporting ... See more keywords
适用于斑块状银屑病的 risankizumab 与 ustekinumab:严格评读
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17971
Abstract: 银屑病是一种导致鳞片状、红疹的皮肤病,其受累部位从仅小面积(如肘关节和膝关节)到更大面积不等。在英国约2%的人患有银屑病。该疾病有许多治疗方法,包括药膏、片剂和注射剂。注射剂称为生物制剂,免疫系统的这种靶向特异性成分对银屑病非常有效。本文的英国作者旨在评估两项比较两种这类生物制剂 risankizumab 和 ustekinumab 的试验(称为 UltIMMa‐1 和 UltIMMa‐2)的质量。上述试验包括来自 14个国家的患者,而且表明risankzizumab较ustekinumab对治疗中度或重度银屑病患者更有效。作者发现上述试验实施良好,这是因为他们招募了大量患者,而且所使用的方法很恰当且进行明确报告。他们采用适当方式分析了数据,该方式保守且未过度估计新疗法risankizumab的疗效。对这些试验的一项批判是在临床环境下(即在实际治疗中而非试验中)可能很难使结果适用于某些患者群体。例如,尚不明确接受片剂或某些其他注射剂治疗并失败的患者是否会出现与从未接受这类治疗的患者不同的反应。此外,某些其他疾病患者被从研究中排除,尽管未说明患有哪些疾病会被排除。作者总结,本次研究明确证明risankizumab比ustekinumab更有效,尽管需要更多工作要做,以确认其中的原因。 read more here.
Keywords: dermatology; risankizumab ustekinumab; ustekinumab risankizumab; risankizumab ... See more keywords
Anti-interleukin-23 for psoriasis in elderly: guselkumab, risankizumab and tildrakizumab in real world practice.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and experimental dermatology"
DOI: 10.1111/ced.14979
Abstract: BACKGROUND Elderly patients (≥65 years) represent an increasing rate of psoriatic patients, 15% have moderate-to-severe disease. Biologics are being frequently used even if safety and efficacy data are limited. OBJECTIVE Evaluate and compare guselkumab, risankizumab,… read more here.
Keywords: risankizumab tildrakizumab; guselkumab risankizumab; risankizumab; practice ... See more keywords
Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.14487
Abstract: Monoclonal antibodies are explored for their therapeutic potential in Psoriasis. To evaluate Risankizumab in the moderate to severe psoriasis with regard to efficacy, tolerability, and safety PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and… read more here.
Keywords: systematic review; severe psoriasis; psoriasis; risankizumab ... See more keywords
Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15489
Abstract: Several new biologic agents targeting IL23/Th17 axis, such as risankizumab, have been developed for the treatment of psoriasis. The aim of the present study was to analyze the efficacy and safety of risankizumab in patients… read more here.
Keywords: risankizumab; moderate severe; week; severe psoriasis ... See more keywords
Successful treatment of a refractory pyoderma gangrenosum with risankizumab
Sign Up to like & getrecommendations! Published in 2020 at "International Wound Journal"
DOI: 10.1111/iwj.13359
Abstract: Dear Editors, A 59-year-old female patient with pyoderma gangrenosum had been in our outpatient care for several years. Her medical history shows that 10 years ago, after a trauma, an ulceration of the left lower… read more here.
Keywords: pyoderma gangrenosum; prednisolone; gangrenosum; therapy ... See more keywords